Treatment of heart failure in non-human mammals with an aldosterone antagonist

Veterinary composition for the treatment of heart deficiency in non-human mammalian subjects, comprises aldosterone antagonist, and vehicles, where the aldosterone antagonist is present in an effective therapeutic dose of greater than 1 mg/kg/day to less than 5 mg/kg/day, preferably 4 mg/kg/day, as...

Full description

Saved in:
Bibliographic Details
Main Authors OVAERT, PATRICIA, GUYONNET, JEROME, BERNAY, FLORENCE
Format Patent
LanguageEnglish
French
German
Published 20.01.2016
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Veterinary composition for the treatment of heart deficiency in non-human mammalian subjects, comprises aldosterone antagonist, and vehicles, where the aldosterone antagonist is present in an effective therapeutic dose of greater than 1 mg/kg/day to less than 5 mg/kg/day, preferably 4 mg/kg/day, as a single dose. An independent claim is included for a veterinary kit for the treatment of heart failure in non-human subjects, comprising at least a compartment comprising a daily dose of the aldosterone antagonist of greater than 1 mg/kg/day to less than 5 mg/kg/day, preferably 4 mg/kg/day. ACTIVITY : Cardiant. MECHANISM OF ACTION : Aldosterone antagonist; Angiotensin converting enzyme inhibitors; Angiotensin II receptor AT-1 antagonists; Beta blocker; Calcium antagonists.
Bibliography:Application Number: EP20120180334